ロード中...
Adjuvant or neoadjuvant chemotherapy for NSCLC
In functionally fit patients with localized disease surgical resection remains the treatment of choice. There is also good evidence to support the use of chemotherapy in stages II-III. However, whether to use neoadjuvant or adjuvant therapy has been the topic of much debate. With its strong evidence...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Pioneer Bioscience Publishing Company
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4032958/ https://ncbi.nlm.nih.gov/pubmed/24868440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2014.04.26 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|